Bayer brings this summer’s M&A highlight with the sale of its veterinary medicine division to Elanco for approx. USD 7.6 billion.
Together with Lanxess, Bayer also sells chemical park operator Currenta to Macquarie for a transaction volume of approx. EUR 3.5 billion. Finally, Bayer lets go of Dr. Scholl’s foot treatment articles to financial investor Yellow Wood for approx. USD 585 million.
For a detailed look into these transactions, plus insights into related developments in domestic and foreign investments, public policy and market conditions during the third quarter, click here.